Alexza Pharmaceuticals Inc.

Alexza Pharmaceuticals Inc. insiders are currently net buyers of ALXA stock, showing bullish sentiment over the past 90 days. Executives have purchased $18.8M while selling $2.1M, resulting in a positive net flow of $16.7M. This buying activity represents 90% of total transaction volume.

Alexza Pharmaceuticals Inc. has 26 active insiders who have filed SEC Form 4 transactions in the past 90 days. Ferrer Internacional, S.a. Grupo (Executive) leads with 2 transactions totaling $17.5M. Thomas Braxton King (Executive) follows with 66 transactions worth $2.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Alexza Pharmaceuticals Inc.'s current score of 90/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $18.8M in purchases versus $2.1M in sales.

The most recent insider transaction occurred on Jun 21, 2016, when Pakianathan Deepika (Executive) disposed of 658 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, ALXA insider trading sentiment is currently bullish with an Alignment Score of 90/100. The net insider flow of $16.7M reflects accumulation, with 90% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Alexza Pharmaceuticals Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ALXA, we track all Form 4 filings—currently showing 292 transactions from 26 insiders over 90 days.

A 10b5-1 plan allows Alexza Pharmaceuticals Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At ALXA, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at ALXA appears discretionary, making insider signals more meaningful.

You can monitor Alexza Pharmaceuticals Inc. (ALXA) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 26 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Alexza Pharmaceuticals Inc.'s current score of 90/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $18.8M in purchases versus $2.1M in sales over 90 days, resulting in a net flow of $16.7M.

SEC Form 4 filings are mandatory reports that Alexza Pharmaceuticals Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ALXA, the most common type is "S" with 13 occurrences. The most recent Form 4 was filed on Jun 21, 2016 by Pakianathan Deepika.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Alexza Pharmaceuticals Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at ALXA represents discretionary decisions with more informational value.